• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

运用分子建模技术探索分枝杆菌氧化磷酸化抑制剂的化学空间。

Exploring the Chemical Space of Mycobacterial Oxidative Phosphorylation Inhibitors Using Molecular Modeling.

机构信息

Department of Chemistry, Saint Mary's University, 923 Robie Street, B3H 3C3, Halifax, NS, Canada.

Department of Chemistry and Physics, Mount Saint Vincent University, 166 Bedford Highway, B3M 2J6, Halifax, NS, Canada.

出版信息

ChemMedChem. 2024 Nov 18;19(22):e202400303. doi: 10.1002/cmdc.202400303. Epub 2024 Sep 20.

DOI:10.1002/cmdc.202400303
PMID:39302818
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11581423/
Abstract

Mycobacteria are opportunistic intracellular pathogens that have plagued humans and other animals throughout history and still are today. They manipulate and hijack phagocytic cells of immune systems, enabling them to occupy this peculiar infection niche. Mycobacteria exploit a plethora of mechanisms to resist antimicrobials (e. g., waxy cell walls, efflux pumps, target modification, biofilms, etc.) thereby evolving into superbugs, such as extensively drug-resistant tuberculosis (XDR TB) bacilli and the emerging pathogenic Mycobacterium abscessus complex. This review summarizes the mechanisms of action of some of the surging antimycobacterial strategies. Exploiting the fact that mycobacteria are obligate aerobes and the differences between their oxidative phosphorylation pathways versus their human counterpart opens a promising avenue for drug discovery. The polymorphism of respiratory complexes across mycobacterial pathogens imposes challenges on the repositioning of antimycobacterial agents to battle the rise in nontuberculous mycobacterial infections. In silico strategies exploiting mycobacterial respiratory machinery data to design novel therapeutic agents are touched upon. The potential druggability of mycobacterial respiratory elements is reviewed. Future research addressing the health challenges associated with mycobacterial pathogens is discussed.

摘要

分枝杆菌是机会性的细胞内病原体,在历史上一直困扰着人类和其他动物,直到今天仍然如此。它们操纵和劫持免疫系统的吞噬细胞,使它们能够占据这个特殊的感染位置。分枝杆菌利用大量的机制来抵抗抗生素(例如,蜡质细胞壁、外排泵、靶标修饰、生物膜等),从而进化成超级细菌,如广泛耐药结核分枝杆菌(XDR TB)杆菌和新兴的致病性脓肿分枝杆菌复合体。这篇综述总结了一些抗分枝杆菌策略的作用机制。利用分枝杆菌是严格需氧的事实,以及它们的氧化磷酸化途径与人类的差异,为药物发现开辟了一条有前途的途径。呼吸复合物在分枝杆菌病原体中的多态性给重新定位抗分枝杆菌药物以对抗非结核分枝杆菌感染的增加带来了挑战。本文还探讨了利用分枝杆菌呼吸机制数据设计新型治疗药物的计算策略。综述了分枝杆菌呼吸成分的潜在成药性。讨论了与分枝杆菌病原体相关的健康挑战的未来研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/514b/11581423/80bde4e4bd8a/CMDC-19-e202400303-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/514b/11581423/67a5de387ff6/CMDC-19-e202400303-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/514b/11581423/7df040c24386/CMDC-19-e202400303-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/514b/11581423/c929e0d8ea16/CMDC-19-e202400303-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/514b/11581423/c6ca78968d2d/CMDC-19-e202400303-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/514b/11581423/287a791fb71a/CMDC-19-e202400303-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/514b/11581423/0b04d627c17e/CMDC-19-e202400303-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/514b/11581423/80bde4e4bd8a/CMDC-19-e202400303-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/514b/11581423/67a5de387ff6/CMDC-19-e202400303-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/514b/11581423/7df040c24386/CMDC-19-e202400303-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/514b/11581423/c929e0d8ea16/CMDC-19-e202400303-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/514b/11581423/c6ca78968d2d/CMDC-19-e202400303-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/514b/11581423/287a791fb71a/CMDC-19-e202400303-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/514b/11581423/0b04d627c17e/CMDC-19-e202400303-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/514b/11581423/80bde4e4bd8a/CMDC-19-e202400303-g006.jpg

相似文献

1
Exploring the Chemical Space of Mycobacterial Oxidative Phosphorylation Inhibitors Using Molecular Modeling.运用分子建模技术探索分枝杆菌氧化磷酸化抑制剂的化学空间。
ChemMedChem. 2024 Nov 18;19(22):e202400303. doi: 10.1002/cmdc.202400303. Epub 2024 Sep 20.
2
[Development of antituberculous drugs: current status and future prospects].[抗结核药物的研发:现状与未来前景]
Kekkaku. 2006 Dec;81(12):753-74.
3
Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.社论:结核杆菌药物靶点的现状与展望以及基于构效关系的抗结核药物设计
Curr Pharm Des. 2014;20(27):4305-6. doi: 10.2174/1381612819666131118203915.
4
Development of narrow-spectrum topoisomerase-targeting antibacterials against mycobacteria.窄谱拓扑异构酶靶向抗菌药物的开发用于抗分枝杆菌。
Eur J Med Chem. 2024 Oct 5;276:116693. doi: 10.1016/j.ejmech.2024.116693. Epub 2024 Jul 19.
5
Lipolytic enzymes inhibitors: A new way for antibacterial drugs discovery.脂肪酶抑制剂:抗菌药物发现的新途径。
Eur J Med Chem. 2021 Jan 1;209:112908. doi: 10.1016/j.ejmech.2020.112908. Epub 2020 Oct 12.
6
[Frontier of mycobacterium research--host vs. mycobacterium].[分枝杆菌研究前沿——宿主与分枝杆菌]
Kekkaku. 2005 Sep;80(9):613-29.
7
[Prospects for development of new antituberculous drugs].[新型抗结核药物的发展前景]
Kekkaku. 2002 Aug;77(8):573-84.
8
Flavonoids as Novel Efflux Pump Inhibitors and Antimicrobials Against Both Environmental and Pathogenic Intracellular Mycobacterial Species.黄酮类化合物作为新型外排泵抑制剂和抗微生物剂,针对环境和致病性细胞内分枝杆菌物种。
Molecules. 2020 Feb 7;25(3):734. doi: 10.3390/molecules25030734.
9
Efflux Pump Inhibitors Against Nontuberculous Mycobacteria.外排泵抑制剂对非结核分枝杆菌。
Int J Mol Sci. 2020 Jun 12;21(12):4191. doi: 10.3390/ijms21124191.
10
Antimicrobial activity of carvacrol and its derivatives on spp.: systematic review of preclinical studies.香芹酚及其衍生物对 spp. 的抗菌活性:临床前研究的系统评价。
Future Med Chem. 2024 Apr;16(7):679-688. doi: 10.4155/fmc-2023-0249. Epub 2024 Feb 23.

本文引用的文献

1
Identification of DprE1 inhibitors for tuberculosis through integrated in-silico approaches.通过整合的计算方法鉴定结核分枝杆菌 DprE1 抑制剂。
Sci Rep. 2024 May 17;14(1):11315. doi: 10.1038/s41598-024-61901-x.
2
Identification of novel hit molecules targeting M. tuberculosis polyketide synthase 13 by combining generative AI and physics-based methods.通过生成式人工智能与基于物理方法相结合,鉴定新型靶向结核分枝杆菌聚酮合酶 13 的命中分子。
Comput Biol Med. 2024 Jun;176:108573. doi: 10.1016/j.compbiomed.2024.108573. Epub 2024 May 8.
3
BacPROTACs targeting Clp protease: a promising strategy for anti-mycobacterial drug discovery.
靶向Clp蛋白酶的细菌蛋白酶体靶向嵌合体:抗分枝杆菌药物发现的一种有前景的策略。
Front Chem. 2024 Jan 31;12:1358539. doi: 10.3389/fchem.2024.1358539. eCollection 2024.
4
Nano-PROTACs: state of the art and perspectives.纳米-PROTACs:现状与展望。
Nanoscale. 2024 Feb 29;16(9):4378-4391. doi: 10.1039/d3nr06059d.
5
Bedaquiline for treatment of non-tuberculous mycobacteria (NTM): a systematic review and meta-analysis.贝达喹啉治疗非结核分枝杆菌(NTM):系统评价和荟萃分析。
J Antimicrob Chemother. 2024 Feb 1;79(2):211-240. doi: 10.1093/jac/dkad372.
6
Mycobacterial cords.分枝杆菌索状结构。
Nat Rev Microbiol. 2023 Dec;21(12):769. doi: 10.1038/s41579-023-00989-w.
7
taxonomy using network analysis-aided, context-uniform phylogenomic approach for non-subjective genus demarcation.基于网络分析辅助、上下文一致的系统发生基因组学方法进行非主观属划分的分类学研究。
mBio. 2023 Oct 31;14(5):e0220723. doi: 10.1128/mbio.02207-23. Epub 2023 Oct 5.
8
The resolution of phagosomes.吞噬体的降解。
Immunol Rev. 2023 Oct;319(1):45-64. doi: 10.1111/imr.13260. Epub 2023 Aug 8.
9
A tale of two inhibitors: diarylquinolines and squaramides.双抑制剂的故事:二芳基喹啉类化合物和螺二酰胺类化合物。
EMBO J. 2023 Aug 1;42(15):e114912. doi: 10.15252/embj.2023114912. Epub 2023 Jul 12.
10
Mechanism of mycobacterial ATP synthase inhibition by squaramides and second generation diarylquinolines.分枝杆菌 ATP 合酶被 squaramides 和第二代二芳基喹啉类化合物抑制的机制。
EMBO J. 2023 Aug 1;42(15):e113687. doi: 10.15252/embj.2023113687. Epub 2023 Jun 28.